REGENXBIO (NASDAQ:RGNX – Get Free Report)‘s stock had its “equal weight” rating reaffirmed by equities researchers at Barclays in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $12.00 price target on the biotechnology company’s stock. Nine equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. Vanguard Group Inc. now owns 3,374,140 shares of the biotechnology company’s stock worth $48,588,000 after purchasing an additional 36,042 shares during the period. REGENXBIO Company Profile(Get Free Report)REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform.